Invitae (NYSE: NVTA), a leading medical genetics company, today presented research demonstrating that genetic findings informed clinical management changes that led to improved seizure control and outcomes in the majority of epilepsy patients with actionable findings. This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs. The findings were present
The state's economic development team is currently pursuing more than 230 potential expansion projects.
PacBio's (PACB) latest acquisition is expected to deliver a differentiated set of products and applications across a wide spectrum of markets.